Developing Next-Generation Therapeutics with Lower Technical Risk
Phenotypeca’s pipeline of novel biologics targets areas of significant unmet medical needs. We focus on areas where our full-genome strain engineering and evolutionary functional genomics can de-risk the technical efficacy and safety risk to create substantial commercial value.
Therapeutic Areas of Focus
- VHH – Developing VHH antibodies against known targets of regulated drugs to deliver superior performance tailored to each market
- Vaccines – Developing multivalent vaccines that overcome key manufacturing constraints to deliver either lower costs and/or breakthrough efficacy
- Regulated biologics – New indication for existing regulatory-approved biological therapeutics
Why It Matters
- Improve Efficacy – We use the platforms at our disposal to improve efficacy using established and tested mechanisms
- Accelerated Development – We deploy optimised strains and harness tried and tested efficacy mechanisms to facilitate efficient and faster development
- Lower Technical Risk – Our platform de-risks efficacy and safety testing while addressing manufacturing hurdles from the outset
- Strategic Partnerships – Built with flexibility for co-development or licensing models
Want to explore co-development or partnering opportunities?
